Recombinant Human HLA class I histocompatibility antigen, B alpha chain (HLA-B), partial

^{In
Stock}

中文名稱：

人HLA-B重組蛋白
品名簡稱：

Recombinant Human HLA-B protein, partial
貨號：

CSB-EP355776HU
說明書：

MSDS Datasheet
規格：

￥1836
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

Greater than 85% as determined by SDS-PAGE.
基因名：

HLA-B
Uniprot No.：

P01889
別名：

(Human leukocyte antigen B)(HLA-B)
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
來源：

E.coli
分子量：

38.9 kDa
表達區域：

25-309aa
氨基酸序列

GSHSMRYFYTSVSRPGRGEPRFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIYKAQAQTDRESLRNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHDQYAYDGKDYIALNEDLRSWTAADTAAQITQRKWEAAREAEQRRAYLEGECVEWLRRYLENGKDKLERADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIV
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標簽：

N-terminal 6xHis-tagged
產品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產品評價

靶點詳情

功能：

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9.; Allele B*07:02: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and mainly a Leu anchor residue at the C-terminus. Presents a long peptide (APRGPHGGAASGL) derived from the cancer-testis antigen CTAG1A/NY-ESO-1, eliciting a polyclonal CD8-positive T cell response against tumor cells. Presents viral epitopes derived from HIV-1 gag-pol (TPQDLNTML) and Nef (RPQVPLRPM). Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (SPRWYFYYL). Displays self-peptides including a peptide derived from the signal sequence of HLA-DPB1 (APRTVALTA).; Allele B*08:01: Presents to CD8-positive T cells viral epitopes derived from EBV/HHV-4 EBNA3 (QAKWRLQTL), eliciting cytotoxic T cell response.; Allele B*13:02: Presents multiple HIV-1 epitopes derived from gag (RQANFLGKI, GQMREPRGSDI), nef (RQDILDLWI), gag-pol (RQYDQILIE, GQGQWTYQI) and rev (LQLPPLERL), all having in common a Gln residue at position 2 and mainly hydrophobic amino acids Leu, Ile or Val at the C-terminus. Associated with succesful control of HIV-1 infection.; Allele B*18:01: Preferentially presents octomeric and nonameric peptides sharing a common motif, namely a Glu at position 2 and Phe or Tyr anchor residues at the C-terminus. Presents an EBV/HHV-4 epitope derived from BZLF1 (SELEIKRY). May present to CD8-positive T cells an antigenic peptide derived from MAGEA3 (MEVDPIGHLY), triggering an anti-tumor immune response. May display a broad repertoire of self-peptides with a preference for peptides derived from RNA-binding proteins.; Allele B*27:05: Presents to CD8-positive T cells immunodominant viral epitopes derived from HCV POLG (ARMILMTHF), HIV-1 gag (KRWIILGLNK), IAV NP (SRYWAIRTR), SARS-CoV-2 N/nucleoprotein (QRNAPRITF), EBV/HHV-4 EBNA4 (HRCQAIRKK) and EBV/HHV-4 EBNA6 (RRIYDLIEL), confering longterm protection against viral infection. Can present self-peptides derived from cytosolic and nuclear proteins. All peptides carry an Arg at position 2. The peptide-bound form interacts with NK cell inhibitory receptor KIR3DL1 and inhibits NK cell activation in a peptide-specific way, being particularly sensitive to the nature of the amino acid side chain at position 8 of the antigenic peptide. KIR3DL1 fails to recognize HLA-B*27:05 in complex with B2M and EBV/HHV-4 EBNA6 (RRIYDLIEL) peptide, which can lead to increased activation of NK cells during infection. May present an altered repertoire of peptides in the absence of TAP1-TAP2 and TAPBPL.; Allele B*40:01: Presents immunodominant viral epitopes derived from EBV/HHV-4 LMP2 (IEDPPFNSL) and SARS-CoV-2 N/nucleoprotein (MEVTPSGTWL), triggering memory CD8-positive T cell response. Displays self-peptides sharing a signature motif, namely a Glu at position 2 and a Leu anchor residue at the C-terminus.; Allele B*41:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.; Allele B*44:02: Presents immunodominant viral epitopes derived from EBV/HHV-4 EBNA4 (VEITPYKPTW) and EBNA6 (AEGGVGWRHW, EENLLDFVRF), triggering memory CD8-positive T cell response. Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Phe, Tyr or Trp anchor residues at the C-terminus.; Allele B*45:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.; Allele B*46:01: Preferentially presents nonameric peptides sharing a signature motif, namely Ala and Leu at position 2 and Tyr, Phe, Leu, or Met anchor residues at the C-terminus. The peptide-bound form interacts with KIR2DL3 and inhibits NK cell cytotoxic response in a peptide-specific way.; Allele B*47:01: Displays self-peptides sharing a signature motif, namely an Asp at position 2 and Leu or Met anchor residues at the C-terminus.; Allele B*49:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ile or Val anchor residues at the C-terminus.; Allele B*50:01: Displays self-peptides sharing a signature motif, namely a Glu at position 2 and Ala or Pro anchor residues at the C-terminus.; Allele B*51:01: Presents an octomeric HIV-1 epitope derived from gag-pol (TAFTIPSI) to the public TRAV17/TRBV7-3 TCR clonotype, strongly suppressing HIV-1 replication.; Allele B*54:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.; Allele B*55:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.; Allele B*56:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Ala anchor residue at the C-terminus.; Allele B*57:01: The peptide-bound form recognizes KIR3DL1 and inhibits NK cell cytotoxic response.; Allele B*67:01: Displays peptides sharing a common signature motif, namely a Pro residue at position 2 and Leu anchor residue at the C-terminus.
基因功能參考文獻：
1. The HLA-B35 allele was significantly more common in patients with rheumatic heart disease than the control group (P = 0.043). The HLA-B44 allele was significantly more common in control patients than in patients with rheumatic heart disease (P = 0.014). PMID: 30119146
2. Studied the association of interferon-lambda 4 (IFNL4)-related polymorphisms and human leukocyte antigen (HLA)-B haplotypes within long-term nonprogressor HIV-1 controllers (LTNP-Cs); HLA-B*57 was independently associated with the LTNP-C phenotype, while IFNL4 genotypes represented independent factors for becoming non-LTNP-C. PMID: 27986689
3. The present work showed in West Algerian population that the HLA-B27 antigen and the variation in the CTLA4 3'UTR region played an important role in the ankylosing spondylitis susceptibility. The heterogeneity of this disease is deduced by genetic difference found between B27+ and B27- groups. PMID: 29675891
4. results reveal strong evidence that the HLA-B*15:02 polymorphism can induce serious cutaneous reactions among Asian carbamazepine users[review, meta-analysis] PMID: 29685430
5. human leukocyte antigen (HLA)-Bw4 is associated with susceptibility to psoriatic disease (PsD), but genetic interactions with their cognate ligand, variably expressed killer cell immunoglobulin like receptor (KIR) 3DL1 alleles PMID: 28801811
6. The present study was conducted to investigate the key genes and the inflammatory signaling pathways involved in HLA-B27-associated acute anterior uveitis (AAU) families. PMID: 29620146
7. rs12524487 in HLA-B/MICA was a genetic risk factor for Takayasu arteritis in a Chinese Han population and rs9366782 in this region was associated with ischemic brain disease in TA but not TA susceptibility. PMID: 28261975
8. Ankylosing spondylitis (AS) patients with B*2704 have a higher risk of uveitis than AS with B*2705 in a north Chinese people. PMID: 27428175
9. this study demonstrates an association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients PMID: 29546073
10. Significant association between the HLA-B*15:02 genotype and the B-75(15) serotype and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Javanese and Sundanese populations. PMID: 29053440
11. this study shows that HLA-B genetic variance is associated with HIV-1 viral load in seroconverters from Zambia and Rwanda PMID: 29289742
12. This analysis showed that HLA-B*58:01 genetic testing before allopurinol initiation is unlikely to be a cost-effective intervention in Malaysia. PMID: 29176400
13. Association of HLA-B*15:02 with phenytoin-induced SJS/TEN is rare in the population studied. PMID: 29076187
14. The SNPs rs116488202 and rs4349859 may have a place in the identification of HLA-B27 in the Turkish population. PMID: 26200952
15. HLA-B18 positive patients more frequently had a higher and faster fibrosis progression rate. PMID: 27241060
16. Our results suggested, for the first time, that HLA-B*51:01 is a risk allele for clindamycin-related cutaneous adverse drug reactions in Han Chinese, especially when clindamycin is administered via intravenous drip. PMID: 27527109
17. HLA-B18 Is risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients PMID: 27779247
18. There is a strong association between HLA-B*27 and ankylosing spondylitis patients in the Kurdistan Region of Iraq. PMID: 26012363
19. identification of theoretical epitopes (motifs) involved in the serological reactivity of several HLA-B*14 products. PMID: 28691368
20. Review/Meta-analysis: Screening of HLA-B*5801 may help patients to prevent the occurrence of allopurinol-induced toxic epidermal necrolysis/Stevens-Johnsons syndrome, especially in populations with a higher (>/= 5%) risk allele frequency. PMID: 28857441
21. The Zhuang population that had the highest frequency of HLA-B*15:02 antigens in China is at high risk for carbamazepine-related Stevens-Johnson syndrome toxic epidermal necrolysis disorder. PMID: 28205426
22. current meta-analysis indicates that HLA-B27, especially, its subtypes (HLA-B27*02 and HLA-B27*04) may be potential risk factors for ankylosing spondylitis PMID: 28526894
23. Alleles B*07, DRB1*07, DRB1*12, and C*03:02 provided the strongest associations with BMI in a healthy Chinese cohort. PMID: 29483183
24. Comparison of the structures reveals that the two TCRs differentially binds NY-ESO-160-72-HLA-B*07:02 complex, and induces differing extent of conformational change of the NY-ESO-160-72 epitope. PMID: 29531227
25. Better licensing of KIR3DL1(+) NK cells in the presence of multiple HLA-Bw4 copies is beneficial prior to seroconversion whereas HLA-Bw4 80(T) may be beneficial during acute hepatitis C PMID: 28412292
26. in the Iranian population, HLA-B*08 confers susceptibility to Graves' disease PMID: 28919585
27. Studied prevalence of HLA-B*5701 allele in HIV-infected children and its association with Abacavir hypersensitivity. PMID: 29242412
28. The immunodominant HLA-B*27:02-restricted Nef response adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV CD8(+) T-cell activity in HLA-B*27:05-positive subjects. PMID: 29167337
29. demonstrates that individuals who are HLA-B *35:02 carriers are at increased risk of developing minocycline related liver injury PMID: 28323125
30. study demonstrated an association between HLA-B*13:01 and dapsone-induced severe cutaneous adverse reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms in nonleprosy patients PMID: 28885988
31. This study showed that distinct genetic markers were associated with phenotype-specific PHT-induced severe cutaneous adverse drug reactions. HLA-B*13:01, HLA-B*56:02/04, and CYP2C19*3 were potential genetic markers of phenytoin-induced drug rash with eosinophilia and systemic symptoms/drug hypersensitivity syndrome in Thai patients. PMID: 28391407
32. The HLA-DRB1*15:01 allele was confirmed to be linked to multiple sclerosis disease in an Italy family. PMID: 28676141
33. In white European people, antithyroid drug-induced agranulocytosis was associated with HLA-B*27:05 and with other SNPs on chromosome 6. PMID: 27157822
34. Crystal structure of HLA-B*5801, a protective HLA allele for HIV-1 infection PMID: 27638468
35. we found for the fi rst time an association between HLA genes and 25OHD concentration. Our results will need to be con fi rmed in a larger sample and preferably with more extensive HLA genotyping (in particular, HLA-A and HLA-C alleles). PMID: 27623983
36. These data implicate the prevalent African allele HLA-B*53:01 in the immunopathogenesis of raltegravir-induced DRESS syndrome. PMID: 28369189
37. Genetically, the strong primary sclerosing cholangitis (PSC) risk factors HLA-B*08 and DRB1*03 were more prevalent in Antineutrophil cytoplasmic antibodies (ANCA) -positive than -negative patients. In UC patients without liver disease, HLA-DRB1*03 was more prevalent in pANCA-positive compared with -negative patients.Antineutrophil cytoplasmic antibodies identified PSC patients with clinical and genetic characteristics. PMID: 27558072
38. This review focuses on the ambivalent role of HLA-B27 in autoimmunity and viral protection correlating its functions to the quantitative and qualitative effects of ERAP1 and ERAP2 polymorphisms on their enzymatic activity. PMID: 28759104
39. The association between HLA-B*57 and pemphigus vulgaris is reported for the first time in the present study. PMID: 28197992
40. Arginine (di)methylated human leukocyte antigen class I peptides, which are asymmetrically dimethylated, most likely by CARM1, are favorably presented by HLA-B*07. PMID: 27503676
41. This study demonstrated that the expression of a single human class I MHC molecule, independent of persistent virus infection, influences the extent of sub frequent chronic neuronal injury or repair in the absence of a class II MHC immune response. PMID: 27855706
42. The HLA-B*50 allele was associated with conversion to myasthenia gravis generalized disease in patients with pure ocular symptoms at disease onset. PMID: 27802446
43. A significantly higher risk of chronic rejection after kidney transplantation was observed when recipient (r) and donor (d) pairs completely lacked the two functional rKIR-dHLA ligand combinations rKIR2DL1/dHLA-C2 and rKIR3DL1/dHLA-Bw4. PMID: 28686681
44. The HLA-B*42, HLA-C*17, HLA-DPA1*03, and HLA-DPB1*105 genotypes were associated with allergic asthma and the HLA-B*48 genotype with the nonallergic phenotype. PMID: 28380482
45. There was no increased risk of rheumatoid arthritis in mothers of children with aspartic acid at position 9 of HLA-B. PMID: 28391248
46. HLA-B*15:13 and HLA-B*15:02 are associated with phenytoin-induced severe cutaneous adverse reactions in a Malay population. PMID: 26927288
47. The study found a strong association between the presence of HLA-B27 and the diagnosis of axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS), but the HLA-B15 is also significantly associated with all subtypes of the disease, predominantly with peripheral spondyloarthritis (pSpA). Additionally, HLA-DR1 and DR4 were associated in a cohort of patients with SpA from Colombia. PMID: 28013432
48. selecting a MICA-matched donor significantly influences key clinical outcomes of HCT in which a marked reduction of GVHD is paramount. The tight linkage disequilibrium between MICA and HLA-B renders identifying a MICA-matched donor readily feasible in clinical practice. PMID: 27549307
49. HLA-B51 is a primary association marker in predisposition to Behcet disease, with IL-23R and IL12A being the additional strongest loci. PMID: 27548383
50. B*07 allele was over represented in cutaneous leishmaniasis patients. PMID: 27301744
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein.
蛋白家族：

MHC class I family
數據庫鏈接：

HGNC: 4932

OMIM: 142830

KEGG: hsa:3106

STRING: 9606.ENSP00000399168

UniGene: Hs.654404